Analysts Set Expectations for BOLT Q1 Earnings

Bolt Biotherapeutics, Inc. (NASDAQ:BOLT) – Stock analysts at HC Wainwright issued their Q1 2025 earnings per share estimates for Bolt Biotherapeutics in a research note issued on Tuesday, March 25th. HC Wainwright analyst E. White anticipates that the company will post earnings per share of ($0.33) for the quarter. HC Wainwright currently has a “Neutral” rating on the stock. The consensus estimate for Bolt Biotherapeutics’ current full-year earnings is ($1.61) per share. HC Wainwright also issued estimates for Bolt Biotherapeutics’ Q2 2025 earnings at ($0.32) EPS, Q4 2025 earnings at ($0.34) EPS, FY2025 earnings at ($1.32) EPS, FY2026 earnings at ($0.56) EPS and FY2027 earnings at ($0.34) EPS.

Bolt Biotherapeutics (NASDAQ:BOLT) last released its earnings results on Monday, March 24th. The company reported ($0.38) earnings per share (EPS) for the quarter, meeting analysts’ consensus estimates of ($0.38). The firm had revenue of $0.01 million for the quarter, compared to analyst estimates of $0.79 million. Bolt Biotherapeutics had a negative return on equity of 69.46% and a negative net margin of 665.56%.

Separately, Stifel Nicolaus lowered their price target on Bolt Biotherapeutics from $1.50 to $1.25 and set a “hold” rating on the stock in a research note on Tuesday. Five equities research analysts have rated the stock with a hold rating, According to data from MarketBeat.com, Bolt Biotherapeutics has an average rating of “Hold” and a consensus target price of $1.13.

Bolt Biotherapeutics Stock Down 0.1 %

Shares of BOLT opened at $0.44 on Friday. The company has a debt-to-equity ratio of 0.21, a quick ratio of 3.16 and a current ratio of 3.16. The company has a 50-day simple moving average of $0.47 and a 200-day simple moving average of $0.55. Bolt Biotherapeutics has a 52 week low of $0.38 and a 52 week high of $1.56. The firm has a market capitalization of $16.82 million, a P/E ratio of -0.26 and a beta of 0.94.

Institutional Investors Weigh In On Bolt Biotherapeutics

Several large investors have recently modified their holdings of the stock. Citadel Advisors LLC bought a new position in shares of Bolt Biotherapeutics during the 4th quarter worth approximately $42,000. Velan Capital Investment Management LP bought a new position in shares of Bolt Biotherapeutics during the fourth quarter valued at $27,000. Squarepoint Ops LLC acquired a new stake in shares of Bolt Biotherapeutics in the 4th quarter valued at $26,000. Millennium Management LLC bought a new stake in shares of Bolt Biotherapeutics in the 4th quarter worth about $25,000. Finally, FMR LLC increased its position in shares of Bolt Biotherapeutics by 33.2% during the 3rd quarter. FMR LLC now owns 115,386 shares of the company’s stock worth $75,000 after purchasing an additional 28,773 shares in the last quarter. 86.70% of the stock is currently owned by institutional investors.

About Bolt Biotherapeutics

Bolt Biotherapeutics, Inc, a clinical-stage biopharmaceutical company, engages in the development of immunotherapies for the treatment of cancer. The company’s lead product candidate BDC-1001, which is in clinical development for the treatment of patients with human epidermal growth factor receptor 2- positive solid tumors, including breast, colorectal, endometrial, and gastroesophageal cancer.